[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ass. Prof. Jan Nyman\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100425599",false,"NCT04822077","Study on Proton Radiotherapy of Thymic Malignancies","PROTHYM - Phase II Non-randomized Study on Proton Radiotherapy Of Thymic Malignancies","PROTHYM","Inclusion Criteria:\n\n* Histological or cytological diagnosis of thymoma or thymic carcinoma.\n* With radical surgery: stage III and IVa and selected stage II with type B2, B3 and thymic carcinoma according to local routine. With non-radical surgery (R1 or R2) or inoperable patient\u002F patient refusing surgery: stage I - IVa, any histology\n* PS WHO 0 - 2.\n* FEV1 \\> 1L or \\>40 % of predicted and CO diffusion capacity \\> 40% of predicted (postoperative measures)\n* Age \\>18 years, no upper age limit.\n* Written informed consent from patients.\n\nExclusion Criteria:\n\n* Masaoka-Koga stage IVb (distant metastases).\n* Pregnancy.\n* Serious concomitant systemic disorder incompatible with the study.\n* Tumour motion \\> 0.5 cm on two repeated 4DCT","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease.\n\nPatients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients.\n\nPrimary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern",[26,27,28],"Cardiotoxicity","Pulmonary Toxicity","Thymus Neoplasms",[30,31,32],"Thymoma","Thymic carcinoma","Proton radiotherapy","RECRUITING","2021-03-25",{"date":36,"type":37},"2021-03-30","ACTUAL",{"date":39,"type":37},"2018-04-18",{"date":41,"type":20},"2029-04-01",{"name":43,"class":44},"Ass. Prof. Jan Nyman","NETWORK",3,""]